VolitionRx priced a public offering of common stock and warrants that could raise gross proceeds of $4.6 million, with additional proceeds possible if warrants are fully exercised. The company said the offering includes 2.96 million shares and warrants for up to 1.48 million additional shares at $1.55 per share, with immediate exercisability and a five-year term. VolitionRx reported a cash balance of about $3.1 million at the end of March and also noted plans to submit Nu.Q cancer assays for reimbursement in France, targeting routine use by the end of 2026. Key takeaway: the financing supports ongoing commercialization and assay development milestones for a portfolio built around nucleosome quantification technologies.